[ad_1]
The data released Friday also includes interim efficacy and safety results from clinical trials, Johnson and Johnson said in a statement.
In December 2020, the company signed an agreement in principle with the GAVI Vaccine Association to vaccinate low- and middle-income countries through the COVAX program initiated by the WHO. Johnson, Johnson and GAVI hope to have a purchase agreement in the near future that will allow them to deliver up to 500 million doses of the vaccine manufactured by Jannsen to COVAX in 2022.
Johnson and Johnson said in late January that the effectiveness of their potential coronavirus vaccine would reach 85 percent.
On February 15, the WHO approved a vaccine developed for emergency use by the British-Swedish pharmaceutical company AstraZeneca and the University of Oxford, manufactured in South Korea and India. Before that, a vaccine called Comirnaty from the American pharmaceutical company Pfizer and the German biotechnology company BionTech was added to the list of vaccines approved by the United Nations Health Organization.
According to WHO, the safety and efficacy of the vaccines are under review under the approval process, and COVAX will only be able to ship the vaccine to countries around the world once the procedure is complete. Inclusion on the WHO list could also speed up each country’s authorization procedure for imports and use of the vaccine.
Cover Image: Kyodo News via Getty Images
[ad_2]
